Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002266 · ClinicalTrials.gov registry record · NA
An Open Parallel Study to Determine the Optimum Dosing Schedule for AS-101 in AIDS/ARC Patients
A NA study of HIV Infections, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.
- Completed
- Registry status
- NA
- Development phase
- 1
- Study location
NCT00002266 is a NA study of HIV Infections that has completed, run by Wyeth is now a wholly owned subsidiary of Pfizer. The trial reports 1 study location across 1 state.
The verdict
NCT00002266, a NA study of HIV Infections, has completed, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.
- COMPLETED
- Registry status
- NA
- Development phase
- 1
- Study location
Study Summary
To compare AS-101 dosing schedules (once a week; 3 times a week; 5 times a week; or 5 times per week on alternate weeks) on the effect on clinical immunology and virus burden in AIDS or AIDS related complex (ARC) patients.
Conditions Studied
Interventions
- DRUG AS-101
Study Locations (1)
Arizona
- Univ of Arizona / Health Science Ctr - Tucson
Trial Details
| Field | Value |
|---|---|
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00002266
The ClinicalTrials.gov registry entry for NCT00002266 describes a study currently listed as completed, categorized as NA. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Wyeth is now a wholly owned subsidiary of Pfizer, which has 167 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with HIV Infections appearing as the primary indexed condition, and to 1 intervention - of which AS-101 is the first listed.
NCT00002266 reports 1 study location spanning 1 distinct geographic area - top geographies include Arizona.
Frequently Asked Questions
What is clinical trial NCT00002266 about?
NCT00002266 is a clinical study titled "An Open Parallel Study to Determine the Optimum Dosing Schedule for AS-101 in AIDS/ARC Patients". To compare AS-101 dosing schedules (once a week; 3 times a week; 5 times a week; or 5 times per week on alternate weeks) on the effect on clinical immunology and virus burden in AIDS or AIDS related complex (ARC) patients.
What is the current status of trial NCT00002266?
This trial is currently completed. It is a NA study.
What conditions does trial NCT00002266 study?
This clinical trial studies the following conditions: HIV Infections.
What interventions are being tested in trial NCT00002266?
The interventions under investigation include: AS-101 (DRUG).
Who is sponsoring clinical trial NCT00002266?
This trial is sponsored by Wyeth is now a wholly owned subsidiary of Pfizer, which has 167 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00002266 being conducted?
This trial has 1 study location across Arizona. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
TRAC-ER Intervention to Reduce Risky Alcohol Use and HIV Risk
RECRUITING · NA
-
Community-based Education, Navigation, and Support Intervention for Military Veterans
RECRUITING · NA
-
WiseApp for Spanish Speakers Living With HIV
RECRUITING · NA
-
Comprehensive HIV and Harm Prevention Via Telehealth
RECRUITING · NA
-
Substance Checking Outreach and Pre-Exposure Prophylaxis (PrEP) Engagement Study
RECRUITING · NA
-
Food as Medicine for HIV and Diabetes
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.